<DOC>
	<DOCNO>NCT00927927</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety , tolerability , pharmacokinetic ( effect body investigated drug ) sign clinical efficacy increase single dos four repeat dos NNC 0142-0002 patient rheumatoid arthritis .</brief_summary>
	<brief_title>First-in-man Trial NNC0142-0002 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Active rheumatoid arthritis , characterized Disease Activity Score ( DAS28 ) 3.2 , diagnosis least three month duration Aged 18 75 year ( inclusive ) Subjects stable dos methotrexate least 4 week prior dose Use highly effective contraception trial ( male female ) A chronic inflammatory autoimmune joint disease RA ( rheumatoid arthritis ) An active latent tuberculosis Any investigational experimental therapy within 4 week 5 halflives ( whichever longer ) prior screen visit A know significant cardiovascular disease Vaccination live virus bacteria within 4 week prior randomization The use concomitant medication prohibit trial ( e.g. , certain DMARDs ( antirheumatic therapy disease modify ) , biologics ( : biotechnologically produce antibody ) , intraarticular corticoidinjections , etc . ) A positive test result human immunodeficiency virus ( HIV ) infection , hepatitis B and/or hepatitis C , tuberculosis skin test Donation great equal 400 ml blood within 8 week prior trial entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>